By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citigroup today lowered revenue estimates for Illumina for the second quarter and for full-year 2011, saying that revenues from a trade-in program for the HiSeq 2000 next-generation sequencing platform would not be a "significant contributor" to total revenues.

Last year, Illumina launched a trade-in program offering customers the opportunity to trade in their Genome Analyzers for the new HiSeq 2000 system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.